Dovramilast

Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (INH)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB) In Vivo Dovramilast (oral gavage, 5, 25, or 50 mg/kg, single) significantly improves antibiotic-mediated bacterial killing and reduces lung pathology. Pharmacokinetic Parameters of Dovramilast in B6D2F1 mice. Sampling time(h) Concentration(ng/ml) CC-11050 only CC-11050+ INH 1 1,331.6±136.97 905.35±594.23 2 1,409.47±140.85 1,309.39±214.08 5 948.85±128.7 1,609.18±167.2 8 820.6±265.98 1,271.73±249.18 24 1.27±1.1 4.96±1.85 T max (h) 2.0 5.0 C max (ng/ml) 1,410 1,610 AUC last (ng × h/ml) 10,200 13,900 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: B6D2F1 miceDosage: 5, 25, or 50 mg/kg Administration: oral, 5, 25, or 50 mg/kg, single Result: Reduced PDE4 expression in mtb-infected mouse lungs. Animal Model: B6D2F1 miceDosage: 5, 25, or 50 mg/kg Administration: oral gavage, 5, 25, or 50 mg/kg, single Result: Improved antibiotic-mediated bacterial killing and reduced lung pathology. Form:Solid IC50& Target:PDE4

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet